Response evaluation after neoadjuvant therapy: evaluation of chemotherapy response score and serological and/or radiological assessment of response in ovarian cancer patients.
Chemotherapy
Debulking surgery
Ovarian cancer
Journal
Archives of gynecology and obstetrics
ISSN: 1432-0711
Titre abrégé: Arch Gynecol Obstet
Pays: Germany
ID NLM: 8710213
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
13
01
2021
accepted:
23
02
2021
pubmed:
5
3
2021
medline:
26
11
2021
entrez:
4
3
2021
Statut:
ppublish
Résumé
The chemotherapy response score (CRS) is a histopathological tool to evaluate response to neoadjuvant chemotherapy (NACT) in high-grade serous ovarian cancer (OC). We critically evaluated the clinical value of CRS and compared its predictive power to standard serological (CA125) and radiological response. A retrospective analysis of 277 OC patients, who received primary chemotherapy, was performed. CRS, serological, and radiological findings were correlated with progression-free (PFS) and overall survival (OS). CRS could be determined in 172 of 277 patients (62.1%). In patients with CRS3, a longer median PFS and OS was observed compared with CRS1/2 patients (31.2 vs. 18.9, P < 0.001; 55.0 vs. 36.1 months, P = 0.050). CA125 and radiological response evaluation were also predictive for PFS and OS. Patients with serological and radiological complete response showed longer PFS (23.0 vs. 14.4, P = 0.011; 21.4 vs. 9.6 months, P < 0.001) and OS (49.5 vs. 29.0, P = 0.003; 45.0 vs. 12.9 months, P < 0.001). Patients with pathological complete response (pCR) had the best median PFS (52.8 months), even compared with non-pCR CRS3 (27.8 months). In the total study cohort, serological, and radiological complete response was better at predicting PFS (hazard ratio 2.23 and 2.77). In this study, evaluation of response to chemotherapy by CRS was not superior to conventional methods (CA125 or radiology). Independent of the evaluation method, response to NACT was predictive of PFS and OS. We observed no added value for CRS as a prognostic marker. The clinical relevance of CRS should be discussed, as no therapeutic consequences result from CRS evaluation.
Identifiants
pubmed: 33661392
doi: 10.1007/s00404-021-06020-y
pii: 10.1007/s00404-021-06020-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1021-1032Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492
doi: 10.3322/caac.21492
pubmed: 30207593
pmcid: 30207593
Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70(1):7–30. https://doi.org/10.3322/caac.21590
doi: 10.3322/caac.21590
pubmed: 31912902
du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 115(6):1234–1244. https://doi.org/10.1002/cncr.24149
doi: 10.1002/cncr.24149
pubmed: 19189349
Rose PG, Nerenstone S, Brady MF et al (2004) Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351(24):2489–2497. https://doi.org/10.1056/NEJMoa041125
doi: 10.1056/NEJMoa041125
pubmed: 15590951
Vergote I, Tropé CG, Amant F et al (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363(10):943–953. https://doi.org/10.1056/NEJMoa0908806
doi: 10.1056/NEJMoa0908806
pubmed: 20818904
Kehoe S, Hook J, Nankivell M et al (2015) Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 386(9990):249–257. https://doi.org/10.1016/s0140-6736(14)62223-6
doi: 10.1016/s0140-6736(14)62223-6
pubmed: 26002111
du Bois A, Baert T, Vergote I (2019) Role of neoadjuvant chemotherapy in advanced epithelial ovarian cancer. J Clin Oncol 37(27):2398–2405. https://doi.org/10.1200/jco.19.00022
doi: 10.1200/jco.19.00022
pubmed: 31403864
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. https://doi.org/10.1016/j.ejca.2008.10.026
doi: 10.1016/j.ejca.2008.10.026
pubmed: 19097774
Rustin GJ, Vergote I, Eisenhauer E et al (2011) Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 21(2):419–423. https://doi.org/10.1097/IGC.0b013e3182070f17
doi: 10.1097/IGC.0b013e3182070f17
pubmed: 21270624
Bohm S, Faruqi A, Said I et al (2015) Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J Clin Oncol 33(22):2457–2463. https://doi.org/10.1200/jco.2014.60.5212
doi: 10.1200/jco.2014.60.5212
pubmed: 26124480
Bohm S, Le N, Lockley M et al (2019) Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated chemotherapy response score (CRS) results. Int J Gynecol Cancer. https://doi.org/10.1136/ijgc-2018-000092
doi: 10.1136/ijgc-2018-000092
pubmed: 31492714
McCluggage WG, Judge MJ, Clarke BA et al (2015) Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Mod Pathol 28(8):1101–1122. https://doi.org/10.1038/modpathol.2015.77
doi: 10.1038/modpathol.2015.77
pubmed: 26089092
The College of American Pathologists. Protocol for the examination of specimens from patients with primary tumors of the ovary, fallopian tube, or peritoneum; Version: OvaryFallopian1.0.0.1. Available from https://documents.cap.org/protocols/cp-ovary-fallopian-tube-peritoneum-2017-v1001.pdf . Accessed: 30 March 2020
The Royal College of Pathologists. Standards and datasets for reporting cancers. Dataset for histopathological reporting of carcinomas and borderline tumours of the ovaries, fallopian tubes and peritoneum, July 2019. Available from https://www.rcpath.org/uploads/assets/63d413b3-ee69-43df-aa7f495e062a4d47/G079-Dataset-for-histopathological-reporting-of-carcinomas-of-the-ovaries-fallopian-tubes-and-peritoneum-For-Publication.pdf . Accessed 30 March 2020
Colombo N, Sessa C, du Bois A et al (2019) ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol 30(5):672–705. https://doi.org/10.1093/annonc/mdz062
doi: 10.1093/annonc/mdz062
pubmed: 31046081
Vallius T, Hynninen J, Kemppainen J et al (2018) (18)F-FDG-PET/CT based total metabolic tumor volume change during neoadjuvant chemotherapy predicts outcome in advanced epithelial ovarian cancer. Eur J Nucl Med Mol Imaging 45(7):1224–1232. https://doi.org/10.1007/s00259-018-3961-z
doi: 10.1007/s00259-018-3961-z
pubmed: 29476227
Winfield JM, Wakefield JC, Dolling D et al (2019) Diffusion-weighted MRI in advanced epithelial ovarian cancer: apparent diffusion coefficient as a response marker. Radiology 293(2):374–383. https://doi.org/10.1148/radiol.2019190545
doi: 10.1148/radiol.2019190545
pubmed: 31573402
Rizzo S, Del Grande M, Manganaro L, Papadia A, Del Grande F (2020) Imaging before cytoreductive surgery in advanced ovarian cancer patients. Int J Gynecol Cancer 30(1):133–138. https://doi.org/10.1136/ijgc-2019-000819
doi: 10.1136/ijgc-2019-000819
pubmed: 31754068
Phillips A, Sundar S, Singh K et al (2018) Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. Eur J Surg Oncol 44(6):760–765. https://doi.org/10.1016/j.ejso.2018.01.097
doi: 10.1016/j.ejso.2018.01.097
pubmed: 29426779